Table 3.
Cox Proportional Hazard Regression Analysis of NOAF
| BMI (kg/m2) | Model 1 | Model 2 | Model 3 | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| ≥30.0 | Reference | Reference | Reference | |||
| 25.0–29.9 | 1.077 (0.506–2.291) | 0.848 | 1.267 (0.591–2.717) | 0.544 | 1.281 (0.597–2.750) | 0.525 |
| 23.0–24.9 | 1.612 (0.747–3.477) | 0.224 | 2.266 (1.042–4.924) | 0.039 | 2.253 (1.031–4.920) | 0.042 |
| <23.0 | 1.636 (0.762–3.515) | 0.207 | 2.776 (1.264–6.097) | 0.011 | 2.884 (1.302–6.392) | 0.009 |
| Continuous (per SD) | 0.946 (0.900–0.995) | 0.030 | 0.906 (0.860–0.954) | <0.001 | 0.899 (0.851–0.949) | <0.001 |
Notes: Model 1 adjusted for sex and age. Model 2 adjusted for sex, age, LA, Killip (II–IV) and CTO. Model 3 adjusted for sex, age, LA, Killip (II–IV) and CTO, eGFR, triglyceride, pNT-proBNP and pTNI.
Abbreviations: NOAF, new-onset atrial fibrillation; BMI, body mass index; eGFR, estimated glomerular filtration rate; CTO, chronic total occlusion; pTNI, peak value of troponin I; pNT-proBNP, peak value of N-terminal pro-B-type natriuretic peptide; LA, left atrium.